PDCD1 and hepatocellular carcinoma: In 2017, U.S. Food and Drug Administration (FDA) granted accelerated approval to the PD-1 checkpoint inhibitor, nivolumab, followed by the approval of another PD-1 inhibitor in 2018, pembrolizumab for advanced HCC patients who had disease progression or suffered from severe adverse events with sorafenib.